Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials
- PMID: 17715246
- DOI: 10.1177/1740774507079252
Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials
Abstract
Background: The Women's Health Initiative (WHI) randomized trial of estrogen plus progestin (E + P) was terminated early based on an assessment of harms exceeding benefits for disease prevention. The results contravened prevailing wisdom and a large body of literature regarding benefits of menopausal hormone therapy. The results and their interpretation have been the subject of considerable debate.
Purpose/methods: To describe the process of developing a trial monitoring plan, the key interim and final data, and to explain the choice of statistical methods used in trial monitoring and reporting.
Results: A formalized monitoring plan was developed using statistical methods that acknowledged protocol-defined design and analysis plans, input of monitoring board members especially regarding the role of various study outcomes, and multiple comparisons. Major early departures from design assumptions concerning treatment effects indicated a need for additional flexibility in safety monitoring. When the trials were stopped early, questions arose as to how closely the statistical methods in published reports should correspond to those defined by protocol or used in monitoring.
Methods: were selected to provide a simple and transparent summary of the primary results, with a cautious interpretation promoted by acknowledgement of multiple testing.
Conclusions: Developing a formal trial monitoring plan with a view towards influencing clinical practice is useful for creating consensus among DSMB members regarding the evidence that would justify stopping a trial and the framework to be used to address statistical complexities. Departures from design assumptions typically occur. These reinforce the role of the DSMB in exercising their judgment, and the judicious adaptation of these statistical guidelines in monitoring and reporting trials. In communicating the results in such circumstances, priority should be given to presenting as fair, accurate and transparent a view of the data and findings as current methods and technology allow.
Comment in
-
Rashomon revisited: two views of monitoring the Women's Health Initiative trials.Clin Trials. 2007;4(3):205-6. doi: 10.1177/1740774507079655. Clin Trials. 2007. PMID: 17715245 No abstract available.
Similar articles
-
Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.Clin Trials. 2007;4(3):218-34. doi: 10.1177/1740774507079439. Clin Trials. 2007. PMID: 17715247
-
Rashomon revisited: two views of monitoring the Women's Health Initiative trials.Clin Trials. 2007;4(3):205-6. doi: 10.1177/1740774507079655. Clin Trials. 2007. PMID: 17715245 No abstract available.
-
Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response.J Natl Cancer Inst Monogr. 2005;(35):113-5. doi: 10.1093/jncimonographs/lgi048. J Natl Cancer Inst Monogr. 2005. PMID: 16287896
-
Statistical issues arising in the Women's Health Initiative.Biometrics. 2005 Dec;61(4):899-911; discussion 911-41. doi: 10.1111/j.0006-341X.2005.454_1.x. Biometrics. 2005. PMID: 16401257 Review.
-
Futility approaches to interim monitoring by data monitoring committees.Clin Trials. 2006;3(6):522-9. doi: 10.1177/1740774506073115. Clin Trials. 2006. PMID: 17170036 Review.
Cited by
-
Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy.J Clin Oncol. 2010 Jun 1;28(16):2690-7. doi: 10.1200/JCO.2009.24.8799. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439627 Free PMC article. Clinical Trial.
-
Postmenopausal estrogen and progestin effects on the serum proteome.Genome Med. 2009 Dec 24;1(12):121. doi: 10.1186/gm121. Genome Med. 2009. PMID: 20034393 Free PMC article.
-
Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials.Am J Epidemiol. 2020 Sep 1;189(9):972-981. doi: 10.1093/aje/kwaa033. Am J Epidemiol. 2020. PMID: 32314781 Free PMC article.
-
Quantitative Framework for Retrospective Assessment of Interim Decisions in Clinical Trials.Med Decis Making. 2016 Nov;36(8):999-1010. doi: 10.1177/0272989X16655346. Epub 2016 Jun 27. Med Decis Making. 2016. PMID: 27353825 Free PMC article.
-
Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience.Stroke. 2014 May;45(5):1408-14. doi: 10.1161/STROKEAHA.113.003925. Epub 2014 Apr 3. Stroke. 2014. PMID: 24699059 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical